150 related articles for article (PubMed ID: 16856907)
1. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Vuolteenaho O; Ala-Kopsala M; Nousiainen T; Hartikainen J
Eur J Haematol; 2006 Aug; 77(2):120-7. PubMed ID: 16856907
[TBL] [Abstract][Full Text] [Related]
2. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Kuittinen T; Husso-Saastamoinen M; Sipola P; Vuolteenaho O; Ala-Kopsala M; Nousiainen T; Jantunen E; Hartikainen J
Bone Marrow Transplant; 2005 Dec; 36(12):1077-82. PubMed ID: 16247436
[TBL] [Abstract][Full Text] [Related]
3. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma.
Nousiainen T; Jantunen E; Vanninen E; Remes J; Vuolteenaho O; Hartikainen J
Eur J Haematol; 1999 Feb; 62(2):135-41. PubMed ID: 10052718
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD
Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
[TBL] [Abstract][Full Text] [Related]
5. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.
Nousiainen T; Vanninen E; Jantunen E; Puustinen J; Remes J; Rantala A; Vuolteenaho O; Hartikainen J
J Intern Med; 2002 Mar; 251(3):228-34. PubMed ID: 11886482
[TBL] [Abstract][Full Text] [Related]
6. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Jantunen E; Kuittinen T; Nousiainen T
Leuk Lymphoma; 2003 Jul; 44(7):1151-8. PubMed ID: 12916867
[TBL] [Abstract][Full Text] [Related]
7. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
8. Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide.
Ozkan HA; Bal C; Gulbas Z
Transfus Apher Sci; 2014 Feb; 50(1):46-52. PubMed ID: 24382557
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
Nousiainen T; Vanninen E; Jantunen E; Remes J; Ritanen E; Vuolteenaho O; Hartikainen J
Clin Sci (Lond); 2001 Dec; 101(6):601-7. PubMed ID: 11724646
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients.
Hoffmann U; Brueckmann M; Bertsch T; Wiessner M; Liebetrau C; Lang S; Haase KK; Borggrefe M; Huhle G
Clin Lab; 2005; 51(7-8):373-9. PubMed ID: 16122147
[TBL] [Abstract][Full Text] [Related]
11. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
[TBL] [Abstract][Full Text] [Related]
12. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy.
Kouloubinis A; Kaklamanis L; Ziras N; Sofroniadou S; Makaritsis K; Adamopoulos S; Revela I; Athanasiou A; Mavroudis D; Georgoulias V
Int J Cardiol; 2007 Nov; 122(3):195-201. PubMed ID: 17289172
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
14. Serial Assessment of Natriuretic Peptides in Patients Undergoing Interventional Closure of the Left Atrial Appendage.
Luani B; Rauwolf T; Groscheck T; Tanev I; Herold J; Isermann B; Schmeisser A; Braun-Dullaeus RC
Heart Lung Circ; 2018 Jul; 27(7):828-834. PubMed ID: 28818408
[TBL] [Abstract][Full Text] [Related]
15. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
[TBL] [Abstract][Full Text] [Related]
16. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
20. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
